Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease

Novartis

Status and phase: Terminated; Phase 2

Conditions: Atherosclerotic Coronary Vascular Disease

Treatments: Drug: Ranolazine 500 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT01562041

CPJMR0032105

Details and patient eligibility

About

The study was designed to evaluate the use of ETT electrocardiogram (ECG) indices as biomarkers in the assessment of atherosclerotic coronary vascular disease (ASCVD).

Enrollment: 14 patients

Sex: All

Ages: 40 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• History of stable coronary artery disease

Exclusion criteria

• Inability or unwillingness to participate in multiple exercise treadmill tests and/or any other requirements of this study as assessed by the Investigator.

  • History of chronic atrial fibrillation.

Other protocol-defined inclusion/exclusion criteria may apply.

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

14 participants in 1 patient group

Ranolazine 500 mg

Experimental group

Description:

Participants received ranolazine 500 milligrams (mg), orally, twice daily (b.i.d.) up to 14 days.

Treatment:

Drug: Ranolazine 500 mg